title: [Characteristics of lymphocytic enzyme status of the newborn after metabolic therapy of pregnant women].
abstract: The enzymatic synthetic activity of peripheral blood lymphocytes was changed in the newborns whose mothers suffered from habitual miscarriages and were administered courses of metabolic therapy as part of combined pathogenetic treatment (basis therapy). Metabolic therapy brought about positive shifts which manifested by a reliable activation of succinate dehydrogenase and alpha-glycerophosphate dehydrogenase, this, in its turn, creating favorable conditions for the functioning of the mother-placenta-fetus metabolic system and being conductive to a better adaptation of the newborns in the early neonatal period. Metabolic therapy brought about a twofold reduction of the incidence of fetal hypoxia and hypotrophy.
mesh_terms: D000026:Abortion, Habitual / Q000517:prevention & control*; D001557:Benzenesulfonates / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D045166:Estradiol Congeners / Q000627:therapeutic use; D005260:Female; D005317:Fetal Growth Retardation / Q000517:prevention & control; D005311:Fetal Hypoxia / Q000517:prevention & control; D005993:Glycerolphosphate Dehydrogenase / Q000097:blood*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007231:Infant, Newborn / Q000097:blood*; D008214:Lymphocytes / Q000201:enzymology*; D010276:Parasympatholytics / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D011247:Pregnancy; D013385:Succinate Dehydrogenase / Q000097:blood*; D014665:Vasodilator Agents / Q000627:therapeutic use; D014971:Xanthinol Niacinate / Q000627:therapeutic use
chemical_list: D001557:Benzenesulfonates; D045166:Estradiol Congeners; D006993:Hypnotics and Sedatives; D010276:Parasympatholytics; D014665:Vasodilator Agents; C001770:sigetin; D004176:Dipyridamole; D014971:Xanthinol Niacinate; D005993:Glycerolphosphate Dehydrogenase; D013385:Succinate Dehydrogenase
vernacular_title: Osobennosti fermentnogo statusa limfotsitov novorozhdennykh pri metabolicheskoĭ terapii u beremennykh.